Kicking Off 2025 Digital Health Fundings

News

BioAge Labs, a clinical-stage biopharmaceutical company developing therapies targeting the biology of aging,?announced a multi-year collaboration?with?Novartis?worth over $500 million. The partnership aims to identify and validate drug targets for treating diseases related to aging by combining BioAge’s proprietary human longevity datasets with Novartis’ expertise in exercise biology and drug discovery.

Caduceus Capital Partners, LLC, a Nashville, TN-based venture capital firm dedicated to investing in and accelerating the growth of digital health startups, launched?Caduceus LAUNCH, an accelerator program designed to fast-track pre-seed digital health startups, driving transformative impact and unlocking profitable growth.

Metsera, a four-year-old New York startup co-founded by?Population Health Partners and ARCH Venture Partners that's developing injectable and oral drugs to treat obesity,?has filed to go public.

Funding

Verdiva Bio, a year-old company developing new treatments for obesity and related health issues, raised a $410 million Series A round co-led by Forbion and General Atlantic. RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures 礼来亚洲基金, and LYFE Capital also participated.

Kardigan, a San Francisco, CA-based heart health company that modernizes cardiovascular drug development, raised USD 300 M in Series A funding.?Perceptive Advisors,?ARCH Venture Partners, and?Sequoia Heritage?led the round. The company intends to use the funds to advance its focus on cardiology's areas of greatest unmet need. This will start with disease opportunities and patient segments that are resistant to or poorly managed by current therapies, including primary and secondary cardiomyopathies leading to heart failure.

Innovaccer, a healthcare AI company based in San Francisco, CA, raised $275M in a Series F funding round. The round combined primary and secondary funding, and participants included B Capital Group, Banner Health, Danaher Ventures LLC, Generation Investment Management, Kaiser Permanente, and M12, Microsoft's Venture Fund.

Aviceda Therapeutics, a Cambridge, MA-based private, clinical-stage biotech company focused on developing new immunomodulators, raised $207.5M in Series C financing. Omega Funds and TCGX led the round, including participation from Enavate Sciences, JEITO, Longitude Capital, Blue Owl Healthcare Opportunities, and other investment firms. The company intends to use the funds to support the ongoing Phase 2b/3 and planned pivotal Phase 3 clinical trial for AVD-104 in geographic atrophy (GA), a vision-threatening condition secondary to advanced age-related macular degeneration, and the expansion into other ophthalmic indications.

Tenvie Therapeutics, a San Francisco, CA-based biotechnology company that engineers small molecules to treat neurological diseases, has raised $200M in funding. The round was led by ARCH Venture Partners, F-Prime Capital, and Mubadala Capital, with participation from other investors.

Windward Bio, a Switzerland-based clinical-stage drug development company, raised $200M in Series A funding. The round was led by?OrbiMed,?Novo Holdings, and Blue Owl Healthcare Opportunities and joined by?SR One Capital Management,?Omega Funds,?RTW Investments, LP,?Qiming Venture Partners,?Quan Capital 泉创资本, and?Pivotal BioVenture Partners. The company intends to use the funds to further enhance its Phase 2 trial investigating WIN378 in severe asthma, with initial clinical readouts expected in 2026.

Timberlyne Therapeutics, a clinical-stage biopharmaceutical company based in San Diego, CA, focused on developing new therapies for autoimmune disorders, has raised $180M in Series A funding. The round was led by?Abingworth,?Bain Capital Life Sciences Fund LP, and?VENROCK HEALTHCARE CAPITAL PARTNERS LP, with participation from?Boyu Capital,?Lilly Asia Ventures 礼来亚洲基金,?Braidwell, and?3H Health Investment.

Tune Therapeutics, a Durham, NC-based epigenome editing company, raised over $175M in Series B funding. The round was led by New Enterprise Associates (NEA), Yosemite, Regeneron Ventures, and Hevolution Foundation. The company intends to use the funds to accelerate the development of its existing pipeline, currently anchored by Tune-401, its clinical-stage epigenetic silencing drug for chronic Hepatitis B (HBV).

Hippocratic AI, a two-year-old Palo Alto startup that develops generative AI tools designed to assist healthcare professionals with tasks such as patient communication, administrative support, and clinical guidance, raised a $141 million Series B round at a $1.64 billion post-money valuation just nine months after completing a Series A.?Kleiner Perkins?was the deal lead, with?General Catalyst,?Andreessen Horowitz, and previous investors NVIDIA, Premji, SV Angel, UHS, and WellSpan Health?also opting in. The company has raised a total of $278 million.

Ottimo Pharma, led by former?Seagen?CEO David Epstein,?raised $140M in Series A, led by OrbiMed, Avoro Capital, and Samsara BioCapital, to advance jankistomig, a PD1-VEGFR2 bifunctional antibody positioned to contend with Keytruda (pembrolizumab)?an immunotherapy drug used to treat certain types of cancer.

Evergreen Nephrology, a Nashville, TN-based company specializing in value-based kidney care, raised $130M in funding. The round was led by Rubicon Founders, Oak HC/FT, and a group of existing investors, with the addition of K2 HealthVentures.

Ouro Medicines, a San Francisco, CA-based biotechnology company developing immune reset therapeutics for people living with chronic immune-mediated diseases, launched with $120m in Series A funding. The Series A was co-led by TPG Life Sciences Innovations, New Enterprise Associates (NEA), and Norwest Venture Partners, with participation from Monograph Capital, GSK, UPMC Enterprises, Boyu/Zoo Capital, LongRiver Investments, and other unnamed investors.?

FIRE1 , a Dublin, Ireland-based connected medical device solutions company, raised $120M in funding. Polaris Partners and Elevage Medical Technologies led the round, joined by new investors Sands Capital and Longitude Capital, and existing investors Andera Partners, Gilde Healthcare, Gimv, the Ireland Strategic Investment Fund, Lightstone Ventures, Medtronic, New Enterprise Associates (NEA), Novo Holdings, and Seventure Partners.

Aspect Biosystems, a biotechnology company in Vancouver, BC, Canada, developing bioprinted tissue therapeutics for regenerative medicine, raised US$115M in Series B funding. Dimension led the round, which included participation from existing and new investors, including Novo Nordisk, Radical Ventures, InBC Investment Corp., Pallasite Ventures Inc., Pangaea Ventures, Rhino Ventures, and T1D Fund.

Geneoscopy, a St. Louis, MO-based life sciences company focused on developing diagnostic tests to advance gastrointestinal health, raised $105M in Series C funding. Bio-Rad Laboratories (NYSE: BIO and BIO.B) led the round, which included participation from Petrichor Technologies, Labcorp (NYSE: LH), Morningside Ventures, Lightchain Capital LLC, NT Investments, Granger Management and Mercy Health, Tri Locum Partners LP, and others. The company intends to use the funds to continue investing in its innovative pipeline of diagnostic tests for inflammatory bowel disease, addressing a critical unmet medical need.

Qventus, Inc, a NYC-based provider of AI-based care automation software for health systems, raised $105M in Series D funding. The round was led by KKR, with additional participation from Bessemer Venture Partners, and new strategic investors, including health systems Northwestern Medicine, HonorHealth, and Allina Health.?The company intends to use the funds to accelerate the development and commercialization of solutions powered by its AI Operational Assistants into new care settings beyond its Surgical Growth and Inpatient Capacity solutions.

Syncromune?, a Florida-based biotech specializing in combination immunotherapies,?raised $100M in Series A?to advance its in situ therapy platform for metastatic solid tumors. Phase 1 trials are underway for its lead candidates, SV-101 and SV-102.

Saluda Medical, a commercial-stage medical device company based in Minneapolis, MN, raised $100M in funding. The round was led by Redmile Group and included existing investors Wellington Management, TPG Life, Fidelity Management And Research Company, and Action Potential Venture Capital. New investor Piper Heartland Healthcare Capital also participated.

Orbis Medicines, a Copenhagen, Denmark-based oral macrocycle drug discovery company, raised €90M in Series A funding. New Enterprise Associates (NEA) led the round with participation from new investors, including Eli Lilly and Company, Cormorant Asset Management, LP, the Export and Investment Fund of Denmark, and founding investors Novo Holdings and Forbion. The company intends to use the funds to develop a pipeline of oral macrocycle drugs, called ‘nCycles,’ focused on validated blockbuster biologic targets.

RhyGaze AG, a biotechnology company developing gene therapies for retinal diseases, is based in Basel, Switzerland, and Philadelphia, PA. The company raised USD 86M in Series A funding. The round was led by?GV (Google Ventures), ARCH Venture Partners,?F-Prime Capital,?and founding investors BGV (BioGeneration Ventures) and Novartis Venture Fund.

Citryll?raises €85M in Series B funding?to advance CIT-013, a monoclonal antibody targeting Neutrophil Extracellular Traps (NETs), into Phase 2a trials for rheumatoid arthritis and hidradenitis suppurativa by 2025. The round was co-led by?Johnson & Johnson Innovation JJDC Inc.,?Forbion, and?Novartis Venture Fund, with participation from?Pureos Bioventures?and existing investors, including?BGV (BioGeneration Ventures),?Seventure Partners, BOM,?Curie Capital BV, and the company’s founders.?

Francis Medical,?a medical device company based in Minneapolis, MN, raised?$80M?in Series C equity funding. The round was led by Arboretum Ventures?and?Solas BioVentures, with participation from Orlando Health Ventures, two additional strategic partners, and previous investors Coloplast and Tonkawa. Francis Medical is committed to developing urological cancer treatments that are tough on cancer and gentle on patients, with a compassionate belief that minimally invasive therapies can effectively treat cancerous tissue.

A2 Biotherapeutics, Inc., a clinical-stage cell therapy company based in Agoura Hills, CA, is developing logic-gated cell therapies to target tumor cells and protect normal cells selectively. The company raised $80M in Series C funding, with backers including The Column Group and Samsara BioCapital.

Normunity, a Boston, MA- and New Haven, CT-based biotechnology company developing new anti-cancer therapies, raised $75M in Series B funding. The round was led by Samsara BioCapital and Enavate Sciences, alongside other new investors Regeneron Ventures, Pfizer, and YK Bioventures, as well as existing investors Canaan Partners, Sanofi, Taiho Ventures, Osage Venture Partners, HongShan Capital Group (HSG), and Connecticut Innovations. The company intends to use the funds to advance its lead program, NRM-823, a first-in-class T cell engager that binds a novel, highly specific tumor target expressed on multiple solid tumors.

AusperBio Therapeutics, Inc. and?Ausper Biopharma Co., Ltd. (collectively?AusperBio), a US and China-based clinical-stage biotechnology company dedicated to advancing targeted oligonucleotide therapies to achieve a functional cure for chronic hepatitis B (CHB), closed a USD 73 million?Series B financing. The round was led by?Hankang Capital, with participation from?Sherpa Capital,?CDH Investments, and a strategic investor, as well as continued participation from existing investors?Qiming Venture Partners,?InnoPinnacle Fund, and?YuanBio Venture Capital. The proceeds will fund the continued Phase 2 development of?AHB-137, AusperBio’s lead investigational therapy, supporting clinical studies in China and global trials, and the development of commercial-scale manufacturing processes. The funding will also facilitate the expansion of the company’s therapeutic pipeline and operational capabilities to drive sustained growth.

Leyden Labs, a mucosal protection platform provider based in Leiden, the Netherlands, raised $70M in funding. The round was led by ClavystBio and Polaris Partners, with participation from Qiming Venture Partners and continued backing from existing investors, including GV (Google Ventures) and Casdin Capital, LLC Capital. Leyden Labs is leveraging its mucosal protection platform to develop a portfolio of candidates against influenza, coronaviruses, and other respiratory viruses through a new class of broadly protective nasal sprays.

XyloCor Therapeutics, Inc., a clinical-stage biopharmaceutical company based in King of Prussia, PA, is developing novel gene therapies for cardiovascular disease. The company raised $67.5M in Series B financing. JEITO Capital led the round, with participation from existing investors EQT, Fountain Healthcare Partners, and Lumira Ventures. The company intends to use the funds to support two double-blind Phase 2 clinical trials of the lead candidate, XC001, demonstrating transformative potential for treating refractory angina.

Alesta Therapeutics, a biotechnology company based in Leiden, Netherlands, focused on developing transformative small molecule therapies for rare diseases, raised €65M in Series A funding. Frazier Life Sciences and Droia Ventures led the round, including participation from Novartis Venture Fund, RTW Investments, LP, RV Invest, Thuja Capital, and SSI Strategy.

Light Horse Therapeutics, a San Diego, CA-based developer of small molecule therapeutics, raised $62M in Series A funding. The round was led by?Versant Ventures?and included?Mubadala Capital,?Bristol Myers Squibb, Taiho Ventures, and?AbbVie. The company has developed a proprietary platform that uncovers novel functional sites in disease-critical targets. The company integrates approaches to build this precision genetic editing-based platform that interrogates proteins in their native environment, providing better discovery of clinical candidates. Its technology challenges conventional drug discovery by identifying novel functional domains and screening for chemistry. This function-first approach is the opposite of traditional screening-first methodologies.

Numab Therapeutics AG, a fifteen-year-old Swiss company that develops antibody-based immunotherapies for treating inflammation and cancer, raised a $55 million Series C round co-led by Cormorant Asset Management, LP, Forbion, HBM Healthcare Investments AG, and Novo Holdings, with previous investors BVF PARTNERS, L.P, Octagon Capital Advisors, RTW Investments, LP, and BlackRock.

Tasca Therapeutics, a biotechnology company focused on small molecule inhibitors for oncology, has raised $52 million in Series A financing. The round was co-led by Regeneron Ventures and Cure Ventures, with participation from The Invus Group. The funds will support the progression of the company’s lead candidate, CP-383, into Phase 1/2 clinical studies and expand its pipeline of drug discovery programs.

Nuritas, an Irish biotech company specializing in AI-powered peptide discovery from natural sources, has raised $42 million?in a Series C funding round. The company plans to use the capital to scale operations and expand its global customer base.

Onkos Surgical, a Parsippany, NJ-based company developing technologies for the musculoskeletal space, received $35M in a Venture Loan Facility from Horizon Technology Finance (NASDAQ: HRZN). Led by CEO Patrick Treacy, Onkos Surgical is an innovator in the musculoskeletal space, developing technologies to address the clinical challenges associated with complex orthopedic procedures. Its portfolio of products provides solutions for adult and pediatric patients who have bone loss from tumors, trauma, or revision of failed orthopedic implants.

GEMMA Biotherapeutics, a Philadelphia, PA-based therapeutics company, closed a?$34m?seed funding. The round was co-led by Double Point Ventures, Bioluminescence Ventures, and Earlybird Venture Capital, with additional backing from?Savanne Life Sciences.

Aerin Medical, a Mountain View, CA-based medical device company, raised $32.5M in funding. Backers included KCK Medtech, Questa Capital Management, OrbiMed, and Ally Bridge Group, with new participation by Ares Management Credit funds. The company aims to expand access to meaningful relief for millions of patients suffering from chronic ENT conditions. Its products, VivAer??for nasal airway obstruction and RhinAer??for chronic rhinitis, leverage Aerin’s proprietary temperature-controlled technology, which allows ENT physicians to improve patients’ symptoms with unique technologies that are appealing alternatives to invasive surgery.

Coave Therapeutics, a Paris, France-based genetic medicines company, raised €32M in Series A funding. The round was led by Novo Holdings A/S and Bpifrance, with Invus and UI Investissement participation alongside existing investors Seroba. Life Sciences, Fund+, Kurma Partners, Omnes, and Turenne Capital Inc. The company intends to use the funds to advance its proprietary ALIGATER? platform to enhance genetic medicines' targeting, specificity, efficacy, and manufacturability with broad clinical applications.

Deciphex, an AI-powered digital pathology company based in Dublin, Ireland, raised €31M in Series C funding. Molten Ventures led the round, including participation from Act Venture Capital, Seroba., Charles River Laboratories (NYSE: CRL), IRRUS INVESTMENTS, HBAN Medtech Syndicate, and NextSteps Capital.

Zeto, a medical technology company based in Santa Clara, CA, raised $31M in Series B funding. The round was led by MindWorks Global (MWG). Zeto specializes in EEG brain monitoring and diagnostics in healthcare. Its wearable devices make brain monitoring accessible in diverse clinical settings, including the ICU, ED, hospitals, offices, and at home.

Qualified Health, a public benefit corporation based in Palo Alto, CA, that provides the infrastructure for generative AI in healthcare, raised $30M in Seed funding. Backers included SignalFire, Healthier Capital, Town Hall Ventures, Frist Cressey Ventures, Intermountain Ventures, and Flare Capital Partners, as well as healthcare and technology sector angels such as Frank Williams, Justin Kan, Bill Veghte, Varsha Rao, and others.

Clear Labs, a San Carlos, CA-based provider of next-generation sequencing (NGS) platforms for diagnostics, raised $30M in Series D funding. The round was led by a strategic investor, along with participation from existing investors, including Counterpoint Global (Morgan Stanley), Felicis, GV (Google Ventures), HBM Genomics, Khosla Ventures, Menlo Ventures, Nimble Ventures, Redmile Group, and Wing Venture Capital.

Pleno Inc. secures $25M to support the 2025 launch?of its Raptor benchtop multiomics instrument, capable of analyzing DNA, RNA, and proteins—Series B funding from?Deerfield Management,?Foresite Capital,?and Medical Excellence Capital, LLC, among others.

Apheris, a Berlin, Germany-based federated computing company focused on the life sciences sector, raised $20.8m in Series A funding.?The round was co-led by OTB Ventures?and?eCapital with participation from Octopus Ventures and Heal Capital.

Neumirna Therapeutics, a Copenhagen, Denmark-based RNA-focused biotech company, raised €20M in Series A funding. Angelini Ventures and Invivo Partners led the round, which included participation from Innovestor’s Life Science Fund and other existing investors. The company intends to use the funds to support the clinical development of its lead asset, NMT.001, a potential disease-modifying Antisense Oligonucleotide (ASO) therapy for drug-resistant epilepsy, expand its R&D capabilities and scale its pioneering drug discovery platform.

Frontier Direct Care, an employer-funded healthcare company based in Harlingen, TX, raised $20M in Series B funding. Mehshah Capital led the round.

PBS Biotech – a provider of single-use bioreactor systems and bioprocess development services – announced it secured $17 million in follow-on growth capital from Avego and BroadOak Capital Partners.

General Proximity, a San Francisco, CA-based biotech platform company, raised $16M in funding. The round was led by Aydin Senkut at Felicis. Other investors included Y Combinator, age1, Modi Ventures,?Wilson Sonsini, as well as several angel investors including?Jeff Dean?(Head of Google AI),?Uri Lopatin?(Khosla, YC, Pardes),?Ben Mann?(Co-Author GPT-3, Co-Founder Anthropic),?Alec Nielsen?(CEO Asimov),?Trevor Martin?(CEO Mammoth),?Juan Benet?(Founder Filecoin),?Nish Bhat?(Co-Founder Color Health),?Jim Dahl(Rock Creek Capital), and De Thompson V (Legends Capital). The company intends to use the funds to accelerate the development of treatments targeting proteins associated with cancer, cardiometabolic disease, neurodegeneration, and longevity.

RheumaGen, a cell and gene therapy company based in Aurora, CO, raised $15M in Series A funding. SPRIM Global Investments and William Taylor Nominees led the round.

Nema Health, a New Haven, CT-based solution provider for virtual trauma and PTSD care, raised $14.5M in Series A funding. Deerfield Management led the round, including new participants CVS Health Ventures, Optum Ventures, .406 Ventures, and GreyMatter.

Relief Cardiovascular, a Costa Mesa, CA-based company developing solutions for the management of heart failure, raised?$12M?in Series A financing. The round was co-led by?Broadview Ventures Inc and Advent Life Sciences, with participation from PACIFIC HEALTH INVESTMENT, INC, Heartwork Capital, and an undisclosed multinational strategic partner.

AerWave Medical, a six-year-old New York startup that uses ultrasound technology to target lung nerves, aims to improve breathing for patients who don't respond well to standard medications. Lucius Partners led the $12 million round.

Oxford Cancer Analytics, an Oxford, UK- and Toronto, Canada-based medtech company developing blood tests for early cancer detection using proteomics and AI, raised USD$11M in Series A funding. The round was led by We Venture Capital?and?Cross-Border Impact Ventures?with participation from return investors?Eka Ventures, and?Civilization Ventures, and new investors?DigitalDx Ventures,?Macmillan Cancer Support,?Aurelium Ventures,?OKG Capital, and angel investors.

Aptitude Medical Systems, a Goleta, CA-based company offering multiple condition testing solutions, raised over $10M from the Bill & Melinda Gates Foundation. The company is accelerating the development and release of its new point-of-care (POC) and Over-The-Counter (OTC) Chlamydia, gonorrhea, and trichomoniasis sexually transmitted infection (STI) test on the Metrix??molecular diagnostics platform.

Twentyeight Health, a NYC-based provider of a digital-first women’s healthcare platform, raised $10M in Series A funding. The round, which brought the total amount to $25M, was led by Seae Ventures, with participation from Impact America Fund, TSEF - The Social Entrepreneurs' Fund, RH Capital, Impact Engine, Gratitude Railroad, and Townhall Ventures.

Siren, a twelve-year-old San Francisco that makes socks that detect diabetic foot ulcers, raised a $9.5 million round. Previous investor?M?lnlycke Health Care?was the deal lead. The company has raised a total of $43 million.

Senseera, a liquid biopsy company based in Jerusalem, Israel, raised $7.1M in Seed funding. Lightspeed led the round, including participation from I-Next Capital and the LOWY MEDICAL RESEARCH INSTITUTE INC Institute. The company intends to use the funds to advance its?GEM BIOMARKERS??liquid biopsy platform, empowered by?cfChIP-seq technology.

Prudentia Sciences, a Cambridge, MA-based provider of an AI-powered technology platform for life sciences, raised $7M in funding. The round was led by GV (Google Ventures), with Iaso Ventures and Virtue participating.

Pepticom Ltd., a Jerusalem, Israel-based AI-driven peptide-based therapeutics company, raised its $6.6m Series A1 funding. The round was led by Japan Israel High Tech Ventures 2 LP with participation from existing investors—the biotech company specializing in the AI-driven discovery of peptide-based therapeutics. The company aims to transform medicine by developing targeted, more effective treatments for serious diseases, including autoimmune disorders, and other high-need therapeutic areas. By harnessing the properties of peptides, Pepticom’s innovative approach creates precision therapies that address complex biological challenges, offering a new frontier in drug development.

Grove AI, a San Francisco, CA-based clinical trial management and intelligence company, raised $4.9M in Seed funding. The round was led by A*, with participation from Afore Capital, LifeX Ventures, Pear VC, Upfront Ventures, and angels, including Ajit Baid, Chloe Yoo, Phuc Truong, and Till Pieper. The company intends to use the funds to continue scaling its team and product to redefine clinical trials from siloed operations into participant-centered ecosystems driven by real-time data.

Vitalic Health, a Boston, MA-based?mental health startup, launched with $4M in seed funding. Backers included Redesign Health?and?Medicare Advantage Majority payor VNS Health?(a national home- and community-based health care payor/provider).

Red Rover Health, Inc., a Des Moines, IA-based company allowing healthcare providers to integrate third-party solutions into their electronic health record (EHR) systems, raised $4M in funding. The round was led by NewShore Partners.

RyboDyn Inc., a San Diego, CA-based biotechnology company developing immunotherapies targeting the dark genome, raised $4M in pre-seed funding. Genedant Capital and SeaX Ventures led the round with SOSV and Swell VC participation.

Esphera SynBio Inc, a synthetic biology company based in Ottawa, Ontario, Canada, raised USD2M in Seed funding. GKCC and FACIT were backers. The Company is a seed-stage biotechnology company combining technologies developed at?McMaster University?and the Ottawa Hospital Research Institute. It uses synthetic biology approaches to modify cells through the expression of proprietary transgenes, causing the production of engineered exosomes that serve as nanomedicines for the treatment and prevention of human disease. The company is developing cancer immunotherapies, vaccines, and immunomodulatory therapies for various human diseases.

VitVio, a London, UK-based company empowering surgical efficiency, patient outcomes, and hospitals’ ROI, raised $2M in Pre-Seed funding. LDV Capital led the round with participation from Bek Ventures (ex-Earlybird), Tiny Supercomputer Investment Company, and angel investors.

Royal Health Inc., a provider of advanced radiology software and workflow solutions based in White Plains, New York, closed a minority investment led by?HealthQuest Capital. The funding amount remained undisclosed.

Arcuro Medical, a Misgav, Israel-based company developing the SuperBall? Meniscal Repair System, raised an undisclosed amount in Series A funding. Varana Capital led the round. Other investors included Trendlines and Consensus Business Group.

Pison, a Boston, MA-based developer of AI-powered neural sensors for cognitive health, wellness, and gesture control, received an investment from Samsung Ventures. The amount of the deal was not disclosed.

RAAPID INC, a Louisville, KY-based healthcare AI company, raised a Series A investment from M12, Microsoft's Venture Fund. The amount of the deal was not disclosed. The company intends to use the funds to expand its Neuro-symbolic AI platform.

Kerna Laboratories, a San Francisco, CA-based AI biotech startup, raised an undisclosed amount in funding. Backers included Gradient, Humba Ventures, Tau Ventures, Pioneer Fund, Focalpoint Partners, and angels, including?Patrick Hsu?(Arc Institute) and?Jacob Kimmel?(NewLimit).

Funds

Biotech Ecosystem Venture Fund, a new fund managed by?Andreessen Horowitz, will invest?$500 million of?Eli Lilly and Company's money in drug development startups.?

Valspring Capital, a Boston, MA-based healthcare-focused growth equity firm, closed its debut fund, Valspring Capital Fund I, at $255m.